Baseline patient demographics and disease characteristics
| Patient demographics | Total (n=13, %) |
| Median age, years (range) | 57 (22–79) |
| Sex | |
| Female | 7 (53.8) |
| Male | 6 (46.2) |
| Race | |
| Caucasian | 9 (69.2) |
| Asian | 2 (15.4) |
| Unknown | 2 (15.4) |
| ECOG Performance Status | |
| 0 | 12 (92.3) |
| 1 | 1 (7.7) |
| Primary Tumor Diagnosis | |
| Non-small cell Lung Cancer* | 3 (23.1) |
| Head and Neck Squamous Carcinoma | 1 (7.6) |
| Cutaneous Squamous Carcinoma of Skin | 1 (7.6) |
| Breast carcinoma† | 5 (38.4) |
| High-grade Glioma | 3 (23.1) |
| Presence of Extracranial Disease | |
| Yes | 4 (30.7) |
| No | 9 (69.3) |
| Neurologic Symptoms of LMM | |
| Yes | 13 (100) |
| No | 0 (0) |
| Baseline CSF cytology | |
| Positive | 6 (46.2) |
| Negative | 7 (53.8) |
| Median CSF White Cell Count (range) | 6 (1–131) |
| Median Serum Absolute Lymphocyte count (range) | 0.91 (0.3–2.4) |
| Disease Characteristics | |
| Prior Chemotherapy | |
| Yes | 10 (76.9) |
| No | 3 (23.1) |
| Prior Brain/Spine Radiotherapy | |
| Yes‡ | 10 (76.9) |
| No | 3 (23.1) |
| No. of Prior Lines of Systemic Therapy | |
| 0 | 3 (23.1) |
| 1 | 1 (7.7) |
| 2+ | 9 (69.2) |
| Any corticosteroids at the time of study enrollment | |
| Yes | 5 (38.4) |
| No | 8 (61.5) |
*Two NSCLCs were PD-L1 <1%, 1 harbored a MET-exon14 skipping alteration; 1 had no oncogenic driver mutation; 1 NSCLC harbored an NRAS mutation and was PD-L1 30%.
†3 patients had HER2-positive breast cancers; and 2 patients had ER-positive/PR-negative/HER-2-negative breast cancers.
‡Whole-Brain Radiation Therapy= 4; Stereotactic Radiosurgery= 1; Focal RT to LMM= 5; all received > 3months before study enrollment.
ECOG, Eastern Cooperative Oncology Group.